Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease
Diem S, Hasan Ali O, Ackermann C, Bomze D, Koelzer V, Jochum W, Speiser D, Mertz K, Flatz L. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease. Cancer Immunol Immunother 2017; 67:39-45.
Sep 11, 2017Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease
Sep 11, 2017Cancer Immunol Immunother 2017; 67:39-45
Diem Stefan, Hasan Ali Omar, Ackermann Christoph J, Bomze David, Koelzer Viktor H, Jochum Wolfram, Speiser Daniel E, Mertz Kirsten D, Flatz Lukas
The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma
Le Moigne R, Chesi M, Bergsagel P, Kraus M, Driessen C, Kiss von Soly S, Yakes F, Wustrow D, Shawver L, Zhou H, Martin T, Wolf J, Mitsiades C, Anderson D, Wang J, Rice J, Lam C, Aftab B, Djakovic S, Dhimolea E, Valle E, Murnane M, King E, Soriano F, Menon M, Wu Z, Wong S, Lee G, Yao B, Wiita A, Rolfe M. The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma. Mol Cancer Ther 2017; 16:2375-2386.
Sep 6, 2017The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma
Sep 6, 2017Mol Cancer Ther 2017; 16:2375-2386
Le Moigne Ronan, Chesi Marta, Bergsagel P Leif, Kraus Marianne, Driessen Christoph, Kiss von Soly Szerenke, Yakes F Michael, Wustrow David, Shawver Laura, Zhou Han-Jie, Martin Thomas G, Wolf Jeffrey L, Mitsiades Constantine S, Anderson Daniel J, Wang Jinhai, Rice Julie, Lam Christine, Aftab Blake T, Djakovic Stevan, Dhimolea Eugen, Valle Eduardo, Murnane Megan, King Emily M, Soriano Ferdie, Menon Mary-Kamala, Wu Zhi Yong, Wong Stephen T, Lee Grace J, Yao Bing, Wiita Arun P, Rolfe Mark
The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer
Heinrich D, van Oort I, Tucci M, Sridhar S, Omlin A, Olmos D, Kramer G, Kindblom J, Keizman D, Daugaard G, Chi K, Cathomas R, Caffo O, Bergman A, Bektic J, Nilsson S. The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer. Clin Genitourin Cancer 2017
Sep 6, 2017The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer
Sep 6, 2017Clin Genitourin Cancer 2017
Heinrich Daniel, van Oort Inge, Tucci Marcello, Sridhar Srikala S, Omlin Aurelius, Olmos David, Kramer Gero, Kindblom Jon, Keizman Daniel, Daugaard Gedske, Chi Kim N, Cathomas Richard, Caffo Orazio, Bergman Andries M, Bektic Jasmin, Nilsson Sten
Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials
van Mackelenbergh M, Weber K, von Minckwitz G, Untch M, Schneeweiss A, Müller V, Kümmel S, Blohmer J, Fasching P, Huober J, Hanusch C, Jackisch C, Stickeler E, Marme F, Schem C, Karn T, Nekljudova V, Denkert C, Loibl S. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Res Treat 2017; 167:59-71.
Sep 5, 2017Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials
Sep 5, 2017Breast Cancer Res Treat 2017; 167:59-71
van Mackelenbergh Marion T, Weber Karsten E, von Minckwitz Gunter, Untch Michael, Schneeweiss Andreas, Müller Volkmar, Kümmel Sherko, Blohmer Jens-Uwe, Fasching Peter A, Huober Jens, Hanusch Claus, Jackisch Christian, Stickeler Elmar, Marme Frederik, Schem Christian, Karn Thomas, Nekljudova Valentina, Denkert Carsten, Loibl Sibylle
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Seddon B, Dehbi H, Nash S, Forsyth S, Tirabosco R, Küver K, Jamieson D, Veal G, Marples M, Ali N, Benson C, Wood Z, Rothermundt C, Cowie F, Woll P, Leahy M, Whelan J, Strauss S, Beare S. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol 2017
Sep 4, 2017Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Sep 4, 2017Lancet Oncol 2017
Seddon Beatrice, Dehbi Hakim-Moulay, Nash Stephen, Forsyth Sharon, Tirabosco Roberto, Küver Katja, Jamieson David, Veal Gareth J, Marples Maria, Ali Nasim, Benson Charlotte, Wood Zoe, Rothermundt Christian, Cowie Fiona, Woll Penella J, Leahy Michael, Whelan Jeremy, Strauss Sandra J, Beare Sandy
Sentinel Lymph Node Mapping with Isosulfan Blue or Indocyanine Green in Colon Cancer Shows Comparable Results and Identifies Patients with Decreased Survival: A Prospective Single-Center Trial
Weixler B, Rickenbacher A, Raptis D, Viehl C, Gueller U, Rueff J, Zettl A, Zuber M. Sentinel Lymph Node Mapping with Isosulfan Blue or Indocyanine Green in Colon Cancer Shows Comparable Results and Identifies Patients with Decreased Survival: A Prospective Single-Center Trial. World J Surg 2017; 41:2378-2386.
Sep 1, 2017Sentinel Lymph Node Mapping with Isosulfan Blue or Indocyanine Green in Colon Cancer Shows Comparable Results and Identifies Patients with Decreased Survival: A Prospective Single-Center Trial
Sep 1, 2017World J Surg 2017; 41:2378-2386
Weixler Benjamin, Rickenbacher Andreas, Raptis Dimitri Aristotle, Viehl Carsten T, Gueller Ulrich, Rueff Jessica, Zettl Andreas, Zuber Markus
Absence of Evidence is not Evidence of Absence: The Case of Non-Inferiority
Klingbiel D, Thürlimann B, Brauchli P, von Moos R. Absence of Evidence is not Evidence of Absence: The Case of Non-Inferiority. Ann Oncol 2017
Aug 31, 2017Absence of Evidence is not Evidence of Absence: The Case of Non-Inferiority
Aug 31, 2017Ann Oncol 2017
Klingbiel D, Thürlimann Beat, Brauchli P, von Moos R
Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm
Tandstad T, Powles T, Lewis M, Grimison P, Bank D, Porter C, Albers P, De Santis M, Srinivas S, Bosl G, Feldman D, Cedermark G, Foster R, Kollmannsberger C, Roth B, Jeldres C, Gillessen Sommer S, Fizazi K, Daneshmand S, Lowrance W, Hanna N, Albany C, Nichols C. Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. J Clin Oncol 2017; 35:3525-3528.
Aug 30, 2017Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm
Aug 30, 2017J Clin Oncol 2017; 35:3525-3528
Tandstad Torgrim, Powles Thomas, Lewis Mark A, Grimison Peter Scott, Bank Douglas, Porter Christopher, Albers Peter, De Santis Maria, Srinivas Sandy, Bosl George J, Feldman Darren R, Cedermark Gabriella Cohn, Foster Richard, Kollmannsberger Christian K, Roth Bruce J, Jeldres Claudio, Gillessen Sommer Silke, Fizazi Karim, Daneshmand Siamak, Lowrance William T, Hanna Nasser H, Albany Costantine, Nichols Craig R
Hilfe beim Sterben, Hilfe zum Sterben oder Hilfe zum Leben?
Brändle M, Büche D, Nestor K. Hilfe beim Sterben, Hilfe zum Sterben oder Hilfe zum Leben? - Sterbehilfe rechtlich, ethisch und palliativ betrachtet. Schweiz Med Forum 2017 2017; 17:738-743.
Aug 30, 2017Hilfe beim Sterben, Hilfe zum Sterben oder Hilfe zum Leben?
Aug 30, 2017Schweiz Med Forum 2017 2017; 17:738-743
Brändle Michael, Büche Daniel, Nestor Karen
Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.06.002
Gillessen Sommer S, de Bono J, Sartor O, Omlin A. Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.06.002. Eur Urol 2017
Aug 28, 2017Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.06.002
Aug 28, 2017Eur Urol 2017
Gillessen Sommer Silke, de Bono Johann S, Sartor Oliver, Omlin Aurelius
Treatment of limited disease small cell lung cancer: the multidisciplinary team
Glatzer M, Rittmeyer A, Müller J, Opitz I, Papachristofilou A, Psallidas I, Früh M, Born D, Putora P. Treatment of limited disease small cell lung cancer: the multidisciplinary team. Eur Respir J. 2017; 50
Aug 24, 2017Treatment of limited disease small cell lung cancer: the multidisciplinary team
Aug 24, 2017Eur Respir J. 2017; 50
Glatzer Markus, Rittmeyer Achim, Müller Joachim, Opitz Isabelle, Papachristofilou Alexandros, Psallidas Ioannis, Früh Martin, Born Diana, Putora Paul Martin
Fear, pain, denial and spiritual expereinces in dying processes
Renz M. Fear, pain, denial and spiritual expereinces in dying processes. Am J Hosp Care 2017
Aug 21, 2017Fear, pain, denial and spiritual expereinces in dying processes
Aug 21, 2017Am J Hosp Care 2017
Renz Monika
Applied Swarm-based medicine: collecting decision trees for patterns of algorithms analysis
Panje C, Glatzer M, von Rappard J, Rothermundt C, Hundsberger T, Zumstein V, Plasswilm L, Putora P. Applied Swarm-based medicine: collecting decision trees for patterns of algorithms analysis. BMC Med Res Methodol 2017; 17:123.
Aug 16, 2017Applied Swarm-based medicine: collecting decision trees for patterns of algorithms analysis
Aug 16, 2017BMC Med Res Methodol 2017; 17:123
Panje Cédric, Glatzer Markus, von Rappard Joscha, Rothermundt Christian, Hundsberger Thomas, Zumstein Valentin, Plasswilm Ludwig, Putora Paul Martin
Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients
Zweifel M, Sessa C, Schoenfeld W, Tapia C, Brauchli P, Hawle H, Pilop C, Rothgiesser K, Bigler M, Pagani O, von Moos R, Weder P, Riniker S, Thürlimann B. Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients. Endocr Connect 2017; 6:549-556.
Aug 16, 2017Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients
Aug 16, 2017Endocr Connect 2017; 6:549-556
Zweifel Martin, Sessa Cristiana, Schoenfeld Wolfgang, Tapia Coya, Brauchli Peter, Hawle Hanne, Pilop Christiane, Rothgiesser Karin M, Bigler Martin, Pagani Olivia, von Moos Roger, Weder Patrik, Riniker Salome, Thürlimann Beat
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Delaunay M, Campana M, Gautschi O, Früh M, Fumet J, Audigier-Valette C, Couraud S, Dalle S, Leccia M, Jaffro M, Collot S, Prévot G, Milia J, Pérol M, Dansin E, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, Michot J, Raimbourg J, Girard N, Guisier F, Planchard D, Metivier A, Tomasini P, Mazières J. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017; 50
Aug 10, 2017Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Aug 10, 2017Eur Respir J. 2017; 50
Delaunay Myriam, Campana Marion, Gautschi Oliver, Früh Martin, Fumet Jean-David, Audigier-Valette Clarisse, Couraud Sébastien, Dalle Stéphane, Leccia Marie-Thérèse, Jaffro Marion, Collot Samia, Prévot Grégoire, Milia Julie, Pérol Maurice, Dansin Eric, Cadranel Jacques, Lusque Amélie, Meyer Nicolas, Gounant Valérie, Moro-Sibilot Denis, Michot Jean-Marie, Raimbourg Judith, Girard Nicolas, Guisier Florian, Planchard David, Metivier Anne-Cécile, Tomasini Pascale, Mazières Julien
Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia
Kampa-Schittenhelm K, Frey J, Haeusser L, Illing B, Pavlovsky A, Blumenstock G, Schittenhelm M. Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia. Oncotarget 2017; 8:82897-82909.
Aug 7, 2017Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia
Aug 7, 2017Oncotarget 2017; 8:82897-82909
Kampa-Schittenhelm Kerstin, Frey Julia, Haeusser Lara A, Illing Barbara, Pavlovsky Ashly A, Blumenstock Gunnar, Schittenhelm Marcus
Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer
Endt K, Joos T, Gillessen Sommer S, Steuber T, Engeler D, Rainisio M, Guenther A, Tennstedt P, Athanasiou A, Omlin A, Goepfert J, Schiess R. Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer. PloS one 2017; 12:e0181557.
Aug 2, 2017Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer
Aug 2, 2017PloS one 2017; 12:e0181557
Endt Kathrin, Joos Thomas, Gillessen Sommer Silke, Steuber Thomas, Engeler Daniel, Rainisio Maurizio, Guenther Anna, Tennstedt Pierre, Athanasiou Alcibiade, Omlin Aurelius, Goepfert Jens, Schiess Ralph
Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer
Pezaro C, James N, Logothetis C, Morgans A, Parker C, Ryan C, Saad F, Sartor O, Small E, Sternberg C, Sweeney C, Tannock I, Tombal B, Hussain M, Higano C, Omlin A, Mastris K, Attard G, Beer T, Chi K, Chowdhury S, Davis I, Drake C, de Bono J, Efstathiou E, Gravis G, Gillessen Sommer S. Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. Ann Oncol 2017; 28:1692-1694.
Aug 1, 2017Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer
Aug 1, 2017Ann Oncol 2017; 28:1692-1694
Pezaro C J, James N, Logothetis C J, Morgans A, Parker C, Ryan C J, Saad F, Sartor O, Small E J, Sternberg C N, Sweeney C J, Tannock I, Tombal B, Hussain M, Higano C S, Omlin Aurelius, Mastris K, Attard G, Beer T M, Chi K N, Chowdhury S, Davis I D, Drake C G, de Bono J S, Efstathiou E, Gravis G, Gillessen Sommer Silke
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Xu B, Osborne K, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Hussein K, Huober J, Huang C, Hayes D, Harbeck N, Pagani O, Partridge A, Pritchard K, Whelan T, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsky P, Gnant M, P Winer E, Burstein H, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Y Brucker S, Bonnefoi H, Curigliano G. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28:1700-1712.
Aug 1, 2017De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Aug 1, 2017Ann Oncol 2017; 28:1700-1712
Xu B, Osborne K C, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Hussein K, Huober J, Huang C-S, Hayes D F, Harbeck N, Pagani O, Partridge A H, Pritchard K, Whelan T J, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E J T, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann Beat, Senn H-J, Piccart-Gebhart M, Regan M M, Colleoni M, Loibl S, Dubsky P, Gnant M, P Winer E, Burstein H J, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Y Brucker S, Bonnefoi H, Curigliano G
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
Möbus V, Thomssen C, Untch M, Nekljudova V, Loibl S, du Bois A, Bauerfeind I, Müller V, Huober J, Fehm T, Conrad B, Harbeck N, Elling D, Tesch H, Schneeweiss A, Lück H, Jackisch C, von Minckwitz G, German Breast Group (GBG), the AGO Breast Study Group (AGO-B) and NOGGO Study Groups. German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients. Ann Oncol 2017; 28:1803-1810.
Aug 1, 2017German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
Aug 1, 2017Ann Oncol 2017; 28:1803-1810
Möbus V, Thomssen C, Untch M, Nekljudova V, Loibl S, du Bois A, Bauerfeind I, Müller V, Huober Jens, Fehm T, Conrad B, Harbeck N, Elling D, Tesch H, Schneeweiss A, Lück H-J, Jackisch C, von Minckwitz G, German Breast Group (GBG), the AGO Breast Study Group (AGO-B) and NOGGO Study Groups